Radiopharmaceutical · Acts on melanocortin-1 receptor (MC1R) · developed by Perspective Therapeutics
Gallium Ga 68-VMT02 is a radioconjugate in which the VMT02 melanocyte-stimulating hormone receptor-targeting moiety is labeled with the positron-emitting isotope gallium Ga 68. VMT02 binds MC1R, a G protein-coupled receptor upregulated on metastatic melanoma cells, allowing those cells to be detected by PET imaging. It is studied in melanoma, including uveal and mucosal melanoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04904120 | Phase 1 | Melanoma (Skin) | Completed | CATX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Melanoma (Skin)Melanoma Stage IVMelanoma, MucosalMelanoma, Uveal
Updated Oct 11, 2026. Something wrong or missing? Report it on the CATX page.
See CATX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CATX catalysts and pipeline →